Independent Portfolio Consultants’s Regeneron Pharmaceuticals REGN Stock Holding History

Independent Portfolio Consultants’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$40K	Buy	81 +15	+23%	+$6.56K	0.02%	545
2017 Q1	$26K	Buy	66 +3	+5%	+$1.11K	0.01%	639
2016 Q4	$23K	Buy	63 +3	+5%	+$1.14K	0.01%	613
2016 Q3	$24K	Buy	+60	New	+$24.1K	0.01%	622
2015 Q2	–	Sell	-1	Closed	–	–	1002
2015 Q1	$0	Buy	+1	New	+$424	﹤0.01%	1035

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Independent Portfolio Consultants's REGN Position: Q2 2017 in Review

Independent Portfolio Consultants increased its Regeneron Pharmaceuticals (REGN) stake by 23% in Q2 2017, buying an estimated $6.56K and bringing the position to 81 shares worth $40K. The position accounts for 0.02% of the portfolio, ranked #545.

Independent Portfolio Consultants first reported a position in REGN in Q1 2015 and has held it in 5 quarters since. 604 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

Independent Portfolio Consultants held 81 shares of Regeneron Pharmaceuticals worth $40K as of Q2 2017.
Independent Portfolio Consultants bought 15 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $6.56K.
Regeneron Pharmaceuticals made up 0.02% of Independent Portfolio Consultants's portfolio in Q2 2017, its #545 holding.
Independent Portfolio Consultants first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 5 quarters since.
604 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.